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Cost-effectiveness data to guide treatment decisions for 
elderly patients: focus on radiotherapy 
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As a disease of the elderly, cancer poses a unique public 
health problem worldwide. Elderly patients with cancer are 
less likely to receive guideline-based treatment and/or 
participate in clinical trials. At the individual patient level, 
competing risk, perceived efficacy of treatment, and various 
levels of patient/physician preferences all contribute to 
heterogeneity in treatment decision-making. At the 
population level, the economic impact of this variability is 
significant. Costs incurred in the prevention, diagnosis, 
treatment and surveillance of cancer are rising at a rate 
disproportionate to what healthcare systems are able to 
afford. Cost-effectiveness research can be employed to 
determine the suitability of radiotherapy in elderly cancer 
populations through modeling or in the context of clinical 
trials.  Using stereotactic radiotherapy in early stage lung 
cancer as an example, the principals of cost-effectiveness 
research will be explored. Concepts such as cost calculations, 
quality adjusted life expectancy, utilities, and incremental 
cost effectiveness ratios will be introduced. 
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Cancer is increasingly becoming a disease affecting the lives 
of the elderly, especially in more developed countries. Over 
the last 30 years, many patients have experienced the 
mortality lowering benefits of earlier diagnosis and more 
effective treatments. At the same time, the elderly 
population is demographically fast increasing, pronouncing 
even higher prevalence and incidence rates in the near 
future. Among other co-morbidities, second or third cancers 
are not an exception any more. 
Because of large individual variations in physical and mental 
conditions and personal preference of the patient and/or 
family, the treatment decisions seem difficult to fit into 
guidelines. Inclusion in clinical trials is rare. 
Overall, elderly receive (adjuvant) radiotherapy 
and chemotherapy less often, probably because of fear 
for higher rate of complications. In clinical surveys, however, 
elderly don´t suffer from more complications than younger 
patients, except for cardiac complications and postoperative 
death. For most tumours relative survival is lower for the 
elderly, except for patients with colon cancer, prostate 
cancer or indolent NHL. Co-morbidity seems to have an 
independent prognostic effect, except for tumours with a 
very poor prognosis. 
Alternative research strategies need to be sought to improve 
insights on causes of death in this population. Special 
attention is needed for the economical impact of over- versus 
under treatment. Both palliative care and complications 
generate high costs, but reports on costs are rare. Often 
quality of life surveys are lacking late outcome and decision-
making trade offs. Registry based surveys can help insights in 
population-based decision-making, but are lacking co-
morbidity and toxicity data. 
Guidelines are needed to reduce over-treatment but also 
under-treatment, taking into account life-expectancy and co-
morbidities in all our cancer patients. 
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More than 60% of cancer patients is older than 65 years, a 
figure that only will increase the coming decades. As elderly 
patients are underrepresented in clinical trials, treatment 
recommendations for the general population cannot 
straightforwardly be extrapolated to the elderly. 
It is anticipated that intensified treatment regimens are less 
effective in elderly due to physiologic changes occurring with 
aging. Furthermore, higher toxicity rates are expected given 
the high rates of comorbidities and generally poorer 
performance status. Hence, the balance between the 
benefits and risks of a treatment will be different for this 
patient group. In fact, this balance will be different for each 
individual elderly patient: although it is reasonable to spare 
the patient with severe comorbidities or a bad performance 
status an intensive treatment from which he is unlikely to 
benefit and that might even decrease quality of life (QoL), 
the one that is medically fit may benefit from such an 
intensive treatment. Furthermore, given the limited life 
expectancy, QoL and preservation of independence and 
cognition are important to take into account.  
For these reasons, there is an urgent need to design clinical 
trials specific for the elderly, build evidence to guide 
treatment selection in this group and implement it in clinical 
practice. First, reliable tools are needed to distinguish the 
subgroup of fit patients from frail patients, i.e. those 
expected to experience important toxicity. Until now, this 
decision is rather subjective as it is based primarily on the 
physician’s perception whether a patient is deemed fit 
enough to undergo a certain treatment. Geriatric 
assessments have shown to be more predictive for survival, 
dependency and toxicities than age or performance status in 
elderly treated with chemotherapy (Freyer, Ann Oncol 2005; 
Hurria, JCO 2011; Maione JCO 2005), but these have not been 
validated for radiotherapy. The fact that a full geriatric 
assessment is time consuming and is not always reimbursed 
makes it difficult to implement in routine clinical practice. 
Therefore, the EORTC recommends a minimum dataset data 
(MinDS) to be collected, which takes max 5 minutes to 
complete (Pallis, Ann Oncol 2011). It is anticipated that this 
